Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00001638 |
This study is directed at evaluating patients with "myocardial ischemia" or poor blood supply to the heart muscle due to coronary artery disease. The major objective of this study is to determine the level of safety and effectiveness of magnetic resonance imaging at diagnosing coronary artery disease.
In addition, this study will allow researchers at the National Institutes of Health to see a broad spectrum of disease, preserve clinical skills, and stimulate future ideas for clinical research....
Condition |
---|
Heart Disease |
Study Type: | Observational |
Official Title: | Cardiovascular Magnetic Resonance Imaging |
Study Start Date: | September 1997 |
This is a teaching protocol. It is in a format for training physicians in the laboratory in cardiovascular MRI techniques necessary for our research protocols. It helps provide experience necessary to develop and maintain our clinical expertise with cardiovascular MRI methods. It also provides physicians in the region access to this technology.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria for All Arms of the Protocol
Exclusion Criteria for All Arms of the Protocol:
Patients with a contraindication to MRI scanning will be excluded. These contraindications include patients with the following devices:
In addition the following patient groups will be excluded:
Furthermore, the following patient groups will be excluded from studies involving the administration of MRI contrast agents:
The eGFR will be used to estimate renal function if reported by the laboratory. Otherwise, estimated glomerular filtration rate (eGFR) can be based on the Modification of Diet in Renal Disease (MDRD) study equation (see below) in subjects with stable renal function. This formula is not applicable to patients with acute renal insufficiency:
eGFR (ml/min/l.73 m(2))= 175 x (serum creatinine)-l.l54 x (age)-0.203 x 0.742 (if the subject is female) x 1.212 (if the subject is black)
Additional Exclusion Criteria for Dobutamine MRI
Additional Exclusion Criteria for Vasodilator Stress MRI
Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
Contact: TTY | 1-866-411-1010 |
United States, Maryland | |
Suburban Hospital | Recruiting |
Bethesda, Maryland, United States, 20814 | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 |
Study ID Numbers: | 970204, 97-H-0204 |
Study First Received: | November 3, 1999 |
Last Updated: | December 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00001638 |
Health Authority: | United States: Federal Government |
Echocardiography Heart Gadolinium Dobutamine Toxicity Adverse Events |
Myocardial Infarction Myocardial Viability Myocardial Perfusion Myocardial Function Cardiovascular Disease |
Heart Diseases Infarction Myocardial Infarction Dobutamine |
Cardiovascular Diseases |